O304
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555641

CAS#: 1261289-04-6

Description: O-304 is a pan-activator of AMP-activated protein kinase (AMPK). It increases levels of phosphorylated AMPK (pAMPK) without reducing cellular ATP. O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients.


Price and Availability

Size
Price

100mg
USD 950
1g
USD 2950
Size
Price

200mg
USD 1450
2g
USD 4950
Size
Price

500mg
USD 2150
5g
USD 6950

O-304, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 555641
Name: O304
CAS#: 1261289-04-6
Chemical Formula: C16H11Cl2N3O2S
Exact Mass: 378.9949
Molecular Weight: 380.243
Elemental Analysis: C, 50.54; H, 2.92; Cl, 18.65; N, 11.05; O, 8.42; S, 8.43


Synonym: O-304; O 304; O304;

IUPAC/Chemical Name: 4-chloro-N-[2-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-1,2,4-thiadiazol-5-yl]-benzamide

InChi Key: WEDWLYRQKUTOAX-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H11Cl2N3O2S/c17-12-5-1-10(2-6-12)9-21-16(23)20-15(24-21)19-14(22)11-3-7-13(18)8-4-11/h1-8H,9H2,(H,19,20,22,23)

SMILES Code: O=C(NC(SN1CC2=CC=C(Cl)C=C2)=NC1=O)C3=CC=C(Cl)C=C3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.90.01


References

1: Das V, Kroin JS, Moric M, McCarthy RJ, Buvanendran A. AMP-activated protein kinase (AMPK) activator drugs reduce mechanical allodynia in a mouse model of low back pain. Reg Anesth Pain Med. 2019 Sep 20. pii: rapm-2019-100839. doi: 10.1136/rapm-2019-100839. [Epub ahead of print] PubMed PMID: 31541009.

2: Das V, Kroin JS, Moric M, McCarthy RJ, Buvanendran A. Antihyperalgesia effect of AMP-activated protein kinase (AMPK) activators in a mouse model of postoperative pain. Reg Anesth Pain Med. 2019 Jun 21. pii: rapm-2019-100651. doi: 10.1136/rapm-2019-100651. [Epub ahead of print] PubMed PMID: 31229963.

3: D'Souza N, Balyasnikova S, Tudyka V, Lord A, Shaw A, Abulafi M, Tekkis P, Brown G. Variation in landmarks for the rectum: an MRI study. Colorectal Dis. 2018 Oct;20(10):O304-O309. doi: 10.1111/codi.14398. Epub 2018 Sep 26. PubMed PMID: 30176118.

4: Steneberg P, Lindahl E, Dahl U, Lidh E, Straseviciene J, Backlund F, Kjellkvist E, Berggren E, Lundberg I, Bergqvist I, Ericsson M, Eriksson B, Linde K, Westman J, Edlund T, Edlund H. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. 2018 Jun 21;3(12). pii: 99114. doi: 10.1172/jci.insight.99114. eCollection 2018 Jun 21. PubMed PMID: 29925691; PubMed Central PMCID: PMC6124394.

5: Riad NM, Zlotos DP, Holzgrabe U. Crystal structure of 5,11-di-hydro-pyrido[2,3-b][1,4]benzodiazepin-6-one. Acta Crystallogr E Crystallogr Commun. 2015 Apr 11;71(Pt 5):o304-5. doi: 10.1107/S2056989015006817. eCollection 2015 May 1. PubMed PMID: 25995917; PubMed Central PMCID: PMC4420050.

6: Ohno K, Fujihara T, Nagasawa A. An ortho-rhom-bic polymorph of N (1),N (4)-diphenyl-3,6-bis-(phenyl-imino)-cyclo-hexa-1,4-diene-1,4-di-amine. Acta Crystallogr Sect E Struct Rep Online. 2014 Mar 29;70(Pt 4):o495-6. doi: 10.1107/S1600536814006254. eCollection 2014 Apr 1. PubMed PMID: 24826185; PubMed Central PMCID: PMC3998558.

7: Yoon YK, Ali MA, Tan SC, Rosli MM, Razak IA. 3-{5-Eth-oxy-carbonyl-1-[3-(2-oxopyrrol-idin-1-yl)prop-yl]-1H-benzimidazol-2-yl}b enzoic acid. Acta Crystallogr Sect E Struct Rep Online. 2013 Feb 1;69(Pt 2):o304. doi: 10.1107/S1600536813001116. Epub 2013 Jan 31. PubMed PMID: 23424569; PubMed Central PMCID: PMC3569823.

8: Yu Y. 7-Chloro-6,8-dinitro-quinazolin-4(3H)-one acetic acid monosolvate. Acta Crystallogr Sect E Struct Rep Online. 2012 Feb 1;68(Pt 2):o304. doi: 10.1107/S1600536811055735. Epub 2012 Jan 7. PubMed PMID: 22346942; PubMed Central PMCID: PMC3274997.

9: Loh WS, Fun HK, Sarveswari S, Vijayakumar V, Reddy BP. 6-Chloro-3-[5-(4-fluoro-phen-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]-2-methyl-4 -phenyl-quinoline. Acta Crystallogr Sect E Struct Rep Online. 2010 Jan 9;66(Pt 2):o304. doi: 10.1107/S1600536810000218. PubMed PMID: 21579737; PubMed Central PMCID: PMC2979872.

10: Zhang M, Yuan XY, Liu XM. 2,2-Dimethyl-5-triphenyl-methyl-1,3-dioxane. Acta Crystallogr Sect E Struct Rep Online. 2009 Jan 14;65(Pt 2):o304. doi: 10.1107/S1600536809000294. PubMed PMID: 21581913; PubMed Central PMCID: PMC2968387.

11: Portalone G, Colapietro M. Nicotinohydrazide. Acta Crystallogr Sect E Struct Rep Online. 2007 Dec 18;64(Pt 1):o304. doi: 10.1107/S1600536807066561. PubMed PMID: 21200868; PubMed Central PMCID: PMC2915352.

12: Batsanov AS, Goeta AE, Howard JA, Soto B, Au-Alvarez O. 2-(4-Chloroanilino)- and 2-(4-methoxyanilino)-1,2-diphenylethanone. Acta Crystallogr C. 2006 May;62(Pt 5):o304-6. Epub 2006 Apr 29. PubMed PMID: 16679611.